Objectives: For most adults with initial clinical presentation of multiple sclerosis (MS), biological disease was likely initiated many years prior. Pediatric-onset MS provides an opportunity to study early disease processes.
While most patients developing multiple sclerosis (MS) experience initial clinical symptom onset in adulthood, the biological mechanisms involved in disease initiation likely manifested many years prior. This has limited the ability to study early MS disease pathogenesis and has also posed a challenge to understanding whether, and to what extent, initiating disease mechanisms identified in animal models such as experimental autoimmune encephalomyelitis translate into the human disease. In comparison to adult-onset MS, pediatric-onset MS, which accounts for 2% to 5% of all MS cases, 1, 2 provides an opportunity to study immunologic mechanisms that may contribute to early disease pathogenesis. Only a portion of all children presenting with initial symptoms of acquired CNS demyelinating syndrome (ADS) will develop further disease activity establishing the diagnosis of MS. [1] [2] [3] The remaining children with ADS represent a population with monophasic CNS-directed inflammation, who will not develop further disease activity. Comparing immune responses of children with ADS who are prospectively ascertained as having either MS (ADS-MS) or monophasic disease (ADS-mono) may therefore provide important insights into early MS disease mechanisms.
A practical challenge in studying children relates to the limited availability of biological samples, and assays that can be applied to small volumes of serum or plasma may provide the greatest utility. Antigen arrays are high-throughput tools for the characterization of antibody response profiles. 4, 5 We and others have used antigen arrays to examine humoral immune responses in patients with MS [6] [7] [8] [9] [10] and in animals with experimental autoimmune encephalomyelitis. 8, 11, 12 Here, we applied antigen arrays to examine the profile and evolution of serum antibodies in a large, prospectively followed cohort of children with ADS, to gain insights into early immunologic mechanisms that may contribute to MS development.
METHODS Standard protocol approvals and patient consents. Details of the Prospective Canadian Pediatric Demyelinating Disease Study protocol, inclusion and exclusion criteria, and clinical characteristics of all participants have been recently described. 13 Protocols and informed consents, obtained for all participants, were approved by the institutional ethics-review boards.
Samples. Serum samples were collected and stored (280°C) using a standardized protocol as part of the Canadian Study, 13 in which participants are followed from time of ADS onset with comprehensive clinical and imaging assessments to ascertain whether they develop new MS-defining disease activity. Serum samples, collected at the time of acute ADS presentation (attack) and 3 months later (follow-up), were randomly allocated to training or test sets. Longer-term (6-to 12-month) follow-up samples from a subset of children were used (stability set) for additional internal validation to assess stability of antibody signatures over time. Only samples from children with $2.5 years of prospective follow-up were included. MS diagnosis was conferred in follow-up based on either a second (investigatorconfirmed) clinical demyelinating attack or by MRI confirmation of dissemination in time according to established criteria. 14 Antigens. Peptide antigens were synthesized at the Biopolymers Antigen microarray production, development, and data analysis. Antigens were spotted in replicates of 6 on SuperEpoxy 2 slides (TeleChem, Sunnyvale, CA) as previously described. 4 The microarrays were blocked with 1% bovine serum albumin, and incubated (2 hours, 37°C) with the test serum in blocking buffer. The arrays were then washed and incubated (45 minutes) with 1:500 dilution of goat anti-human immunoglobulin G (IgG) Cy3-conjugated detection antibodies (Jackson ImmunoResearch Labs, West Grove, PA). Arrays were scanned with a ScanArray 4000X scanner (GSI Lumonics, Billerica, MA). Normalized raw data were analyzed using the GeneSpring software (Silicon Genetics, Redwood City, CA). Antigen reactivity was defined by the mean intensity of binding to the replicates of that antigen on the microarray, and expressed as relative fluorescence units.
RESULTS Serum autoantibody reactivities in ADS-MS
compared with ADS-mono during the incident acute demyelinating event. Using serum samples obtained at the time of incident presentation with ADS, we initially analyzed antibody response profiles in a training set of 40 children with ADS, including 20 children subsequently confirmed to have MS (ADS-MS) and 20 children who remained monophasic (ADS-mono). Differences between the 2 groups were observed for antibodies directed against 48 antigens ( figure 1A and table e-4). Reactivities to 24 of these antigens were higher in the ADS-MS group while reactivities to the 24 other antigens were higher in the ADS-mono group. Thirteen of the 24 antibodies (54%) exhibiting higher reactivity in the ADS-MS sera were reactive to CNS antigens (figure 1B); 12 of these 13 antigens (86%) were among those previously implicated in adult MS ( figure 1C ). Fourteen of the 24 antibodies (58%) that exhibited higher reactivity in the ADSmono samples were reactive to CNS antigens (figure 1B), while only 2 of these 14 (15%) were implicated as targets in adult MS (p , 0.0004, figure 1C ). There was no effect of sex or age at time of sampling, nor did differences between polysymptomatic vs monosymptomatic presentations skew the results (data not shown). These findings indicate that, although CNS-reactive antibodies can be detected in both ADS-mono and ADS-MS samples, the antibodies of children with ADS-MS more frequently react with CNS antigens that were previously linked to adult MS pathogenesis.
Discriminating power of serum autoantibody profiles in ADS-MS and ADS-mono during the incident acute demyelinating event. To initially assess the potential discriminating power of the IgG antibody reactivity profiles shown in table e-4, we performed a leaveone-out cross-validation (LOOCV) analysis within the same training set. The number of true (correct) and false (incorrect) classifications was computed to estimate success rate, positive predictive value (PPV; the fraction of patients with ADS-MS correctly identified as ADS-MS by their antigen microarray reactivity), and negative predictive value (NPV; the fraction of patients with ADS-mono correctly identified as ADS-mono by their antigen microarray reactivity) in the training set. The LOOCV revealed a PPV of 0.900 and an NPV of 0.950. We also generated receiver operating characteristic curves by plotting the sensitivity against 1 2 specificity and calculating the area under the curve (AUC) for each population. The AUC is a measure of the ability of the model to discriminate between ADS-mono and ADS-MS. 15 Receiver operating characteristic analysis of the classifier built using the IgG reactivities in the training set produced an AUC of 0.952 ( figure 2A and table e-5). Because the LOOCV was performed on the same sample cohort (training set) used to generate the model, performance of the classifier may reflect overfitting of the model. Thus, we next evaluated the performance of the same classifier on an independent test set composed of additional samples (14 ADSmono and 14 ADS-MS samples), also collected at the time of ADS presentation. We found that the pattern of IgG antibody reactivity identified in the training set could classify the test set of samples with a PPV of 0.785, an NPV of 0.857, and an AUC of 0.872 ( figure 2B and table e-5).
Serum autoantibody reactivities and their discriminating power in ADS-MS and ADS-mono samples obtained in follow-up (3 months after the incident acute demyelinating event). Serum antibodies recognizing myelin oligodendrocyte glycoprotein have been previously reported at the time of ADS in both ADS-mono and ADS-MS children, however these antibodies tended to persist only in the children with ADS-MS. 16 We therefore wished to examine whether the evolution of serum antibody reactivities measured in our antigen array would differ between our ADS-MS and ADS-mono groups over time. We applied the identical antigen arrays in parallel to a training set of serum samples obtained 3 months after the acute ADS presentations of 19 patients with ADS-MS and 20 with ADS-mono. We identified a pattern of 84 IgG antibody reactivities that appeared to discriminate ADS-MS from ADS-mono in these follow-up samples ( figure 1D and table e-6). Sixty-eight of the 84 IgG reactivities were higher in ADS-MS samples; 55 of these 68 antibody reactivities (81%) targeted CNS antigens ( figure 1B) . In comparison, only 7 of the 16 antibody reactivities (44%) associated with ADSmono were directed against CNS antigens (p , 0.0001, Fisher exact test) ( figure 1B) . Moreover, 54 of the 55 CNS antigens (98%) targeted in ADS-MS correspond to putative disease targets implicated in adult MS, as opposed to 2 of the 7 antigens (29%) targeted in ADS-mono samples (p , 0.0001, Fisher exact test) ( figure 1C ).
To analyze the discriminating power of the serum IgG antibody reactivities detected during follow-up of the demyelinating event, we initially performed an LOOCV in a training set of 20 ADS-mono and 19 ADS-MS serum samples taken 3 months after an acute demyelinating attack. The LOOCV produced a PPV of 0.842 and an NPV of 0.900; the AUC was 0.866 ( figure 3A and table e-7) . Analysis of the performance of this IgG-based classifier on a test set of additional 15 ADS-mono and 8 ADS-MS samples also taken 3 months after an acute demyelinating attack revealed a PPV of 1.000 and an NPV of 0.625, and an AUC of 0.833 for the classifier ( figure  3B and table e-7). Finally, we evaluated the stability of the classifiers constructed based on the IgG antibody reactivities measured at 3 months' follow-up using samples obtained in longer-term follow-up (up to 12 months after ADS) from a subset of children. Testing the antibody reactivity classifier in this stability cohort (comprised of 10 ADS-mono and 11 ADS-MS samples) revealed an AUC of 0.727, a PPV of 0.700, and an NPV of 0.545 ( figure 3C and table e-7) . Early detection of intra-and intermolecular antigen spreading in patients with ADS-MS. Taken together, our data suggest an expansion of the initial antibody response to CNS antigens in ADS-MS samples, compatible with the development of intra-and intermolecular epitope spreading. To address whether this apparent expansion in CNS antibody reactivity in children with ADS-MS relative to those with ADS-mono results from increased CNS damage in children with MS, we took advantage of the prospective coregistered brain MRIs acquired on all participants in the Canadian Study, and calculated the volume of T2 hyperintense brain lesions as an overall measure of inflammatory disease burden. The T2 lesion volumes at initial presentation did not differ significantly between the ADS-MS and ADS-mono cohorts (p 5 0.23) and, moreover, the change in T2 volumes assessed between the time of presentation and the follow-up time point (follow-up T2 volume minus presentation T2 volume) was also not different between groups (figure 4; p 5 0.89) indicating that the observed expansion of the antibody response in the ADS-MS group relative to the ADS-mono group is not the result of an increased volume of injured CNS tissue. In further support that epitope spreading explains the expansion in CNSreactive antibodies seen in the children with MS is the detailed analysis of antibody responses to particular myelin antigens and their epitopes ( figure 1E ). While only a few epitopes of proteolipid protein and myelin basic protein were targeted in ADS-MS samples taken at the time of the attack, a significant spreading of the antibody response was detected during follow-up, consistent with "intramolecular" epitope spreading. This intramolecular epitope spreading was not detected in the ADS-mono cohort. Moreover, while no antibodies to CNPase were detectable at the time of ADS in all children, we detected antibodies to multiple CNPase epitopes in follow-up samples of the children with MS consistent with "intermolecular" epitope spreading-again, a phenomenon not observed in the ADS-mono follow-up samples. DISCUSSION In the present study, we measured serum antibody profiles in samples obtained from children with incident ADS at the time of initial attack and 3 months later, and compared these response profiles between children subsequently ascertained as having MS (ADS-MS) vs those children who remained with a monophasic illness (ADSmono). Although both groups of children harbored serum antibodies reactive with CNS antigens, the breadth and specificity of the antibody responses were different. At the time of incident attack, ADS-MS and ADS-mono sera reacted against similar numbers of CNS antigens; however, ADS-MS samples displayed increased antibody reactivities to antigens linked to adult MS. Three months after the incident attack, sera from patients with ADS-MS reacted against a broader panel of CNS antigens, while patients with ADSmono exhibited a contraction in their CNS antibody responses over the same period. The observation that MRI T2 lesion loads did not differ between the ADS-MS and ADS-mono cohorts and, in particular, that the changes in T2 lesion burden diminished to the same extent between the ADS presentation and follow-up in both patient groups indicates that the expansion of the antibody response seen in the ADS-MS group was not simply attributable to an increase in the volume of involved tissue. One notes that antibodies detected with antigen microarrays may be of low affinity, and their pathologic significance is unknown. At the same time, given their relative sensitivity, 5,10 autoantibody patterns detected by the antigen microarrays used here might not be captured by more standard assays such as ELISA. We confirmed acceptable reproducibility of our antigen microarray technique, with repeat measurements exhibiting a coefficient of variation of 13.2 6 1.2, and further supported by our finding that the stability set of follow-up samples also had a high classifier AUC value (0.727), which is similar to a previously reported MS disease classifier that was generated based on combined genetic and environmental factors in adult patients with MS 15 (AUC approximately 0.7). While findings from our stability set provide a measure of internal validation of our results, external validation in an independent cohort will clearly be needed to more fully assess the generalizability of our findings.
Our observations are compatible with a process of molecular epitope spreading in children with ADS-MS, in contrast to the apparent control of CNS inflammation in patients with ADS-mono. Diversification of antigenic specificities from the initial epitope-specific immune response can be to additional epitopes of either the same (intramolecular) or different (intermolecular) antigens. 17 T-cell epitope spread, previously described in experimental models of MS (mice and marmosets) 18 and considered in patients with MS, 19 is thought to be driven by antigen-presenting cells exposed to an expanding repertoire of CNS antigens. 20, 21 Epitope spread can also occur for autoantibody responses (humoral epitope spread). Robinson, Steinman, and coworkers described a broad diversification of antibody responses in experimental models of MS and rheumatoid arthritis, detectable as early as 1 month after disease induction, 12, 22 and autoantibody epitope spread has also been implicated in patients with type 1 diabetes 23 and systemic lupus erythematosus. 24 Our observation that pediatric ADS-MS serum samples obtained 3 months after incident ADS presentation exhibit expanded antibody reactivities (against additional epitopes of the same CNS antigens as well as additional CNS antigens that did not appear to be targeted at the time of the acute demyelinating attack) provides what we believe is the first evidence of autoantibody epitope spread in the serum of patients with MS, and indicates that both intra-and intermolecular humoral epitope spreading can occur as early features of the human disease.
Of interest is whether the contracted CNS reactivities observed over time in the ADS-mono group, in contrast to the epitope spreading noted in patients with ADS-MS, reflects a relative failure in these young patients with MS to regulate aberrant CNSdirected autoantibody responses. Such a defect in immune regulation would be consistent with abnormalities in T-cell immune-regulatory mechanisms described in adult-and pediatric-onset patients with relapsing-remitting MS. [22] [23] [24] [25] If true, our data may reflect deficits in immunoregulation of targetdirected B-cell responses in early MS, allowing the development of humoral epitope spreading as part of the ongoing CNS inflammation observed in these children. 3 We cannot comment on whether or not the autoantibody epitope spread we detect in children with ADS-MS actually contributes to further CNS injury, or whether it emerges as a secondary phenomenon due to ongoing tissue injury. Similarly, we are unable to determine which antigen or antigens initiate the CNS-specific immune response in these patients. It should also be noted that our current work is based on antibody analyses in serum samples as opposed to CSF, 9 which would be expected to provide more direct insights into early disease targets and epitope spreading. Indeed, recent proteomic analysis of CSF obtained from pediatric ADS-MS and ADSmono patients has implicated novel antigens of the axoglial apparatus (not present on the current antigen array) as potential early targets in MS. 26 While epitope spreading may be more challenging to ascertain in serum, our study benefited from repeat sampling in a relatively large cohort of children with MS and controls; a similar approach using CSF samples would be very challenging. Future work incorporating newly implicated antigens into antigen arrays and access to both serum and CSF from wellcharacterized cohorts will be of considerable interest, as would development of other approaches assessing antigen-specific responses in early-onset MS. Such work may help to guide strategies aimed at boosting immunoregulatory mechanisms and/or controlling effector T cells at the antigen-specific level, such as DNA vaccines 6, 7 or the induction of regulatory T cells by stimulation of immunoregulatory molecular pathways with small molecules 11, 27 or nanoparticles, 28 as used to control epitope spreading and CNS inflammation in experimental models of MS.
